June 30, 2026 · Phase 2 readout
EDSA Phase 2 readout: a positive outcome, +6.0%
On June 30, 2026, Edesa Biotech, Inc. reached its Phase 2 readout. The result was a positive outcome, and the stock moved +6.0% in the window around the event. It had already run +13.4% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.
The move
$7.67
1d before
$8.13
Event day
$7.75
1d after
$7.50
5d after
Our prediction vs. the result
CatalystAlert called this one neutral (+0.6% expected); the stock actually moved +6.0%. Model confidence at the time: 40%.
See the full scored track recordPre-catalyst setup
+13.4%
30-day run-up
12948%
30-day volatility
0.3×
volume spike